Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7973040 | MERCK SHARP DOHME | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(6 years from now) | |
US8871759 | MERCK SHARP DOHME | Inhibitors of hepatitis C virus replication |
May, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 9, 2024 |
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET;ORAL
17
United States
4
China
4
European Union
3
Denmark
3
Hong Kong
3
Slovenia
3
Hungary
3
Croatia
3
Cyprus
3
Spain
3
Korea, Republic of
3
Poland
3
RS
3
Japan
3
ME
2
Israel
2
South Africa
2
Mexico
2
Australia
2
Lithuania
2
Morocco
2
Norway
2
Costa Rica
2
Singapore
2
Colombia
2
Brazil
2
Portugal
2
Malaysia
2
Netherlands
2
Dominican Republic
2
Peru
2
Ecuador
2
Luxembourg
2
Ukraine
2
Nicaragua
2
EA
2
Canada
2
Tunisia
2
New Zealand
1
El Salvador
1
Honduras
1
Argentina
1
Chile
1
Taiwan, Province of China
1
Georgia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic